| Study Name | Indication | Description | Location | Stipend | Apply |
|---|---|---|---|---|---|
| AFFINITY (PSA2003) | Psoriatic Arthritis | A Phase 2a, Multicenter, Randomized, Double-blind Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis | Vandalia, Ohio | $936 | Apply |
| SOLSTICE (PSA3005) | Psoriatic Arthritis | A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants with Active Psoriatic Arthritis who had an Inadequate Response and/or Intolerance to One Prior Anti-Tumor Necrosis Factor [alpha] Agent | Vandalia, Ohio | $1300 | Apply |
| STAR (PSA4002) | Psoriatic Arthritis | A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants with Active Psoriatic Arthritis Axial Disease | Vandalia, Ohio | $1300 | Apply |
| LG Gout (LG-GDCL010) | Gout | A Randomized, Multi-regional, Double-blind, Double-dummy Parallel-group, Placebo and Allopurinol-controlled Phase 3 Study to Assess the Efficacy and Safety of Tigulixostat in Gout Patients with hyperuricemia | Vandalia, Ohio | $2165 | Apply |
| NEPTUNUS-01 | Sjogren's Syndrome | A randomized, double-blind, placebo-controlled, 2-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjögren’s syndrome (NEPTUNUS-1) | Vandalia, Ohio | $1638 | Apply |
| APEX (PSA3004) | Psoriatic Arthritis | A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab in Improving the Signs and Symptoms and Inhibiting Radiographic Progression in Participants with Active Psoriatic Arthritis. | Springboro, Ohio | $1040 | Apply |